The price of Arcus Biosciences Inc (NYSE:RCUS) shares last traded on Wall Street rose 2.97% to $9.35.
RCUS stock price is now 9.45% away from the 50-day moving average and -27.77% away from the 200-day moving average. The market capitalization of the company currently stands at $990.03M.
With the price target enhanced from $18 to $24, H.C. Wainwright Upgraded its rating from Neutral to Buy for Arcus Biosciences Inc (NYSE: RCUS). On October 21, 2024, H.C. Wainwright recently initiated its ‘Neutral’ rating on the stock quoting a target price of $20, while ‘Wells Fargo’ rates the stock as ‘Overweight’
In other news, KANEKO YASUNORI, Director bought 20,000 shares of the company’s stock on Feb 27 ’25. The stock was bought for $201,200 at an average price of $10.06. Upon completion of the transaction, the Director now directly owns 28,400 shares in the company, valued at $0.27 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 27 ’25, Chief Executive Officer ROSEN TERRY J bought 19,800 shares of the business’s stock. A total of $201,465 was incurred on buying the stock at an average price of $10.18. This leaves the insider owning 2,554,160 shares of the company worth $23.88 million. A total of 39.66% of the company’s stock is owned by insiders.
During the past 12 months, Arcus Biosciences Inc has had a low of $6.50 and a high of $18.98. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 5.37, and a quick ratio of 5.37.
The net profit margin was -277.30% and return on equity was -63.17% for RCUS. For the current quarter, analysts expect RCUS to generate $32.86M in revenue.
